Veradermics, Incorporated
Every calculator, already run for MANE
Open the full toolkit →You have the numbers on MANE. Get the argument.
A written report on which of these readings actually decide the outcome for Veradermics, Incorporated, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
7 analysts covering MANEAnalyst Price Target Disagreement for Veradermics, Incorporated
Wall Street's bull case implies +79% from the current price; the bear case implies +33%. A 46% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for MANE
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, a…
MANE — frequently asked
Is MANE a buy right now?
Wall Street's consensus rating on Veradermics, Incorporated is Strong Buy across 7 analysts, with a mean price target of $163.50 (+61% vs. the current $101.70). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is MANE's next earnings date?
Veradermics, Incorporated is next scheduled to report earnings around Nov 12, 2026. A full MANE research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Veradermics, Incorporated?
Analysts covering Veradermics, Incorporated (MANE) range from a bear-case target of $135.00 to a bull-case high of $182.00, with a mean consensus target of $163.50 across 6 analysts. The spread of $47.00 (46% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Veradermics, Incorporated against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Veradermics, Incorporated
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full MANE research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Veradermics, Incorporated, in minutes. 3 free reports included with every account — no credit card required.